Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor cell membrane protein vaccine
- Development stage
- Unknown
- Lead developer
- Shenzhen Second People’s Hospital
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
An autologous cancer vaccine composed of membrane proteins extracted from a patient's own tumor cells. Developed by Shenzhen Second People's Hospital, this therapeutic approach aims to stimulate the patient's immune system to recognize and attack tumor cells by presenting a broad spectrum of patient-specific tumor-associated antigens (TAAs) found on the cell membrane. By utilizing the entire repertoire of membrane-bound proteins, the vaccine is designed to overcome tumor heterogeneity and reduce the risk of immune escape. It is being investigated in Phase 1/2 clinical trials for the treatment of various recurrent or metastatic solid tumors, including lung adenocarcinoma, small cell lung carcinoma, hepatocellular carcinoma, pancreatic cancer, colorectal cancer, and breast cancer.
- Other names
- tumor cell membrane therapytumor cell membrane protein vaccineautologous tumor cell membrane protein vaccine therapy
Beyond the preview
Go deeper on autologous tumor cell membrane protein vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor cell membrane protein vaccine.